Posters featured in this tour:

CO15: A Matching-Adjusted Indirect Comparison of Efgartigimod Versus Ravulizumab for Generalized Myasthenia Gravis

EE382: Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK

EE274: Orphan Drug Pricing Comparisons in Low-, Middle- and High-Income Countries

EE147: Estimating the Causal Effect of Early Use of Erythropoietic Stimulating Agents in Intermediate-1 to Low-Risk MDS Patients: An Application of the Longitudinal Targeted Maximum Likelihood Estimation

HPR17: Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England

SA73: Addressing Unmet Needs of Patients With Neuronopathic Gaucher Disease Type 2 and Type 3: Creation of the GARDIAN Patient Registry